#RRP patients face an avg. of 4 surgeries a year. Some face 100s of surgeries over a lifetime. Today, surgery is the standard of care. But with every single RRP patient in mind, we’re working to change the treatment paradigm for this rare and devastating disease. #RareDiseaseDay
关于我们
INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. Our mission: deliver on the promise of DNA medicine for patients around the world. For more information, visit www.inovio.com.
- 网站
-
https://www.inovio.com
INOVIO Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Plymouth Meeting，PA
- 类型
- 上市公司
- 领域
- DNA medicines、DNA plasmids、HPV-associated disease、cancer、infectious diseases、coronaviruses、immuno-oncology、dMAb (DNA-encoded monoclonal antibodies)、immunotherapy、DNA vaccines、high-risk HPV、cervical dysplasia、cervical cancer、cervical HSIL、vulvar HSIL、anal HSIL、recurrent respiratory papillomatosis (RRP)、HPV-associated cancers、head and neck cancer、glioblastoma、prostate cancer、Ebola、Zika、MERS、COVID-19、HIV、Lassa、T cells、SynCon、CELLECTRA和electroporation
地点
INOVIO Pharmaceuticals, Inc.员工
-
Nicole Rich
Senior Director - Commercial Development at INOVIO Pharmaceuticals, Inc.
-
Laurent Humeau
Chief Scientific Officer and Executive Vice President of Research and Development
-
Shawn Bridy, MA, MBA
Senior Vice President, Business Development at INOVIO Pharmaceuticals, Inc.
-
ROBERT GUTHRIE
Manufacturing Electrical Engineer in Pharmaceutical Industry
动态
-
On #RareDiseaseDay we’re shining a light on #RRP & raising awareness for the thousands of patients suffering from this devastating HPV-related disease. Learn more about RRP here: https://bit.ly/3F86lqe
-
-
Today Nature Communications published the clinical and immunological data for INO-3107, showing that it has the potential to become the preferred therapeutic option for #RRP if approved, based on clinical benefit, tolerability and a patient-centric dosing regimen acknowledging that every surgery matters for patients. ? Dr. Peter Belafsky, Director of the Center for Voice & Swallowing at UC Davis Health, and a principal investigator on the trial, said: “The Phase 1/2 study showed the majority of participants experienced a reduced need for surgery, providing great hope for RRP patients who face both risk of vocal cord damage and immense impact on their daily lives with every surgery. INO-3107 was designed with those patient needs in mind and has the potential to transform the treatment paradigm for RRP.” ? INOVIO thanks all of the patients and investigators who were a part of this important trial. For more details, please see our press release: https://bit.ly/41bEoGD
-
-
On the 10th International Day of Women and Girls in Science we’re celebrating all the women who have helped advance science to improve the world, and all the future female scientists who will follow in their footsteps. Special mention of the many incredible women who have played a critical role in DNA science, including: - Discovering mobile genetic elements (Barbara McClintock) - Helping prove that DNA is the genetic material of life (Martha Chase) - Contributing to the discovery of the DNA double helix (Rosalind Franklin) - Inventing CRISPr-Cas9 gene editing (Jennifer Doudna and Emmanuelle Charpentier) #WomenInScience #DNA #DNAMedicine
-
Additional immune?response data for lead candidate INO-3107 will be presented as a poster at AACR IO – read more: https://bit.ly/416pr8O
-
-
??Congrats to Dr. Domchek! Her research at the Penn Medicine Basser Center for BRCA on using #DNAMedicine to protect people with BRCA1/2 mutations could be truly groundbreaking for cancer prevention.?
Congratulations to Dr. Susan Domchek on being awarded the 2025 American Society of Clinical Oncology (ASCO)-American Cancer Society Cancer Prevention Award! The award is annually bestowed upon a distinguished expert who has made significant contributions to cancer prevention and control research or practice. “Dr. Domchek’s work has made an incredible impact on countless individuals and their families who are affected by inherited cancer-associated gene mutations,” said Alison Loren, MD, chief of Hematology-Oncology. “We’re proud to see her efforts recognized through this special award from her peers at #ASCO.” Learn more about Dr. Domchek's remarkable work as the executive director of the Penn Medicine Basser Center for BRCA on genetic susceptibility to cancers and cancer interception: https://spr.ly/6046xcG0E
-
CEO Jacqui Shea & CMO Mike Sumner will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 PM ET. A link to the live webcast or replay of the presentation is available here: https://bit.ly/3KXGeTd #OPCOLifeSciences
-
-
INOVIO shares anticipated 2025 milestones and 2024 accomplishments—read more here: https://bit.ly/4gJhA6L
-
-
Heading to #JPM2025? INOVIO will be in San Francisco next week to meet with investors and potential partners – looking forward to sharing the progress we’ve made developing our DNA medicine portfolio.?
-
-
The INOVIO team was honored to participate at the second-ever RECURRENT RESPIRATORY PAPILLOMATOSIS FOUNDATION RRP Roundtable, where experts, patients and industry representatives came together to discuss innovative ways to advance #RRP research, patient care and advocacy. As a community we are better together!
-